CytoMed's Technologies

CytoMed is translating its patent-pending technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based "off-the-shelf"
immunotherapeutics for a wide range of cancers.

CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using
our proprietary technologies for our customers.

#01

iPSC-γδ NKT Cell Technology
(gdNKT Therapy)

#02

CAR-γδ T Cell Technology
(CTM-N2D Therapy)

CytoMed Therapeutics

Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) and focuses on translating its patented technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers.

CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using our proprietary technologies for our customers.

Read More

Publications

View All Publications
B2 miceta-roglobulin knockout K562 cell-based artificial antigen presenting cells for ex vivo exp...

Chen C,Du Z,Li Z,Tay JC,Wang S,Zha S,

Immunotherapy 2021, 11: 967

Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers

Tay JC,Wang S,Zha S,

Immunotherapy 2021, 9: 1339

Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy

Chen C,Chi Z,Du SH,Kwang TW,Li Z,Tan WK,Wang S,Xu XH,

PLOS ONE 2021, 11: e0161820

CXCR1 expression to improve anti-cancer efficacy of intravenously injected CAR-NK cells in mice w...

Ng YY,Tay JC,Wang S,

Molecular Therapy 2021, 16: 75

Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenog...

Ang WX,Chen C,Chi Z,Li Z,Ng YY,Tan WK,Tay JC,Toh HC,Wang S,Xiao L,Zeng J,

Molecular Therapy 2021, 17: 421

Antigenically modified human pluripotent stem cells generate antigen-presenting dendritic cells

Wang S,Wu C,Zeng J,

Scientific Reports 2021, 5: 15262

Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells

Du J,Palanisamy N,Wang S,Zeng J,Zhao Y,

Stem Cells 2021, 25: 1055

Derivation of mimetic γδ T cells endowed with cancer recognition receptors from reprogrammed γδ T...

Tang SY,Wang S,Zeng J,

PLOS ONE 2021, 14: e0216815

Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d...

Shahbazi M,Toh HC,Wang S,Wu C,Zeng J,

The Journal of Immunology 2021, 188: 4297

Generation of “off-the-shelf” natural killer cells from peripheral blood cell-derived induced plu...

Tang SY,Toh LL,Wang S,Zeng J,

Stem Cell Reports 2021, 9: 1796